The great ablate.
The FDA has granted Varian a breakthrough device designation for its cardiac radioablation system for refractory ventricular tachycardia, placing it on the fast track for approved use off-trial. | Varian 2021
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
The FDA has granted Varian a breakthrough device designation for its cardiac radioablation system for refractory ventricular tachycardia, placing it on the fast track for approved use off-trial. | Varian 2021
Comments
Post a Comment